PAC-113
Phase 2- Indications
- Oral candidiasis, Gingivitis
Company intelligence / Profile preview
PAC‐113 demonstrated positive Phase IIb results in oral candidiasis with efficacy comparable to Nystatin. The company shifted focus to commercialization of consumer health products under sublicense arrangements after acquisition.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pacgen Life Science Corporation.